CN201012180Y - Conjunctiva sac medicament sustained release film - Google Patents

Conjunctiva sac medicament sustained release film Download PDF

Info

Publication number
CN201012180Y
CN201012180Y CNU2007201153508U CN200720115350U CN201012180Y CN 201012180 Y CN201012180 Y CN 201012180Y CN U2007201153508 U CNU2007201153508 U CN U2007201153508U CN 200720115350 U CN200720115350 U CN 200720115350U CN 201012180 Y CN201012180 Y CN 201012180Y
Authority
CN
China
Prior art keywords
drug
dulling
diluting
carrier
eye
Prior art date
Application number
CNU2007201153508U
Other languages
Chinese (zh)
Inventor
浩 崔
Original Assignee
浩 崔
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浩 崔 filed Critical 浩 崔
Priority to CNU2007201153508U priority Critical patent/CN201012180Y/en
Application granted granted Critical
Publication of CN201012180Y publication Critical patent/CN201012180Y/en

Links

Abstract

The utility model is a drug diluting-dulling film for conjunctiva film, which relates to a drug diluting-dulling film. The purpose of the utility model is to overcome the shortcoming that the eyedrop will fast be diluted after being dropped in the eye and some eyedrop will be discharged out of the eye with the tear; so the drug will be wasted, and the drug function will be transitory with unstable curative effect; even, the drug function will be lost completely. The utility model consists of a drug diluting-dulling carrier (1) and a drug (2); the drug (2) is absorbed inside of the drug diluting-dulling carrier (1). Because the device uses the drug absorbed inside of the drug diluting-dulling carrier to bring the drug diluting-dulling carrier into the eye just like wearing the contact lens, the affranchising of the drug will be constant and permanent; the curative effect of the device is clear with saving the drug. The material of the drug diluting-dulling carrier (1) is a multi-hole diluting-dulling material, such as collagen, lipid body, polyethylene alcohol, acetum, hydroxide butyric acid ester, hydroxyl butyric acid- hydroxyl valeric acid (PHBV), PHBV and glutin double-structure material, ethylic cellulose, crylic acid colophony or fruit hydrophile gel and so on.

Description

结膜囊药物缓释膜技术领域本实用新型涉及一种药物缓释膜。 BACKGROUND conjunctiva drug release film of the present invention relates to a pharmaceutical sustained release membrane. 背景技术现有的眼部用药,特别是眼药水点入眼内后,很快被泪液稀释, 一部分眼药水随泪液排出眼外,这样一方面浪费了药物,另一方面使药物作用短暂、疗效不稳定,甚至完全失去治疗作用。 BACKGROUND ART A conventional ocular administration, especially after the eye drops eyes, tear quickly diluted with a portion of the tear drops discharged outside the eye, which wastes the drug, the drug effect on the other hand short, the effect is not stable or even complete loss of therapeutic effect. 实用新型内容本实用新型的目的是为解决眼药水点入眼内后,很快被泪液稀释, 一部分眼药水随泪液排出眼外,这样一方面浪费了药物,另一方面使药物作用短暂、 疗效不稳定,甚至完全失去治疗作用的问题,提供一种结膜囊药物缓释膜。 SUMMARY The present invention aims to solve the eye drops in the eyes, the tear quickly diluted with a portion of the tear drops discharged outside the eye, which wastes the drug, the drug effect on the other hand short, the effect is not stable or even complete loss of issues therapeutic effect, provide a drug delivery conjunctival sac membrane. 本实用新型具有药物释放恒定持久、疗效确切的特点。 The invention has the constant drug release lasting and effective features. 本实用新型由药物缓释载体1和药物2组成,药物2吸附在药物缓释载体1内。 The present invention is a pharmaceutical composition of the drug delivery carrier 1 and 2, adsorption of drug in a drug delivery carrier. 本实用新型具有如下有益效果:由于药物被吸附在药物缓释载体内,将该药物缓释载体如同佩戴隐形眼镜一样戴入眼内,因此药物释放恒定持久、疗效确切、节省药物。 The present invention has the following advantages: As the drug is absorbed in the drug delivery carrier, the drug delivery system as wear contact lenses as wear in the eyes, and therefore a constant drug release lasting, effective, saving drugs. 附图说明图1是本实用新型的整体结构示意图,图2是图1的AA剖视图,图3 是具体实施方式二的结构示意图,图4是图3的BB剖视图。 BRIEF DESCRIPTION OF DRAWINGS FIG. 1 is a schematic view of the present invention the overall novel configuration, FIG 2 is an AA sectional view of FIG. 1, FIG. 3 is a schematic structural diagram of two particular embodiments, and FIG. 4 is a sectional view BB of FIG. 3. 具体实施方式具体实施方式一:(参见图1、图2)本实施方式由药物缓释载体1和药物2组成,药物2吸附在药物缓释载体1内,药物缓释载体l的底端面为圆形3。 DETAILED DESCRIPTION OF EMBODIMENTS Embodiment 1 Referring to FIG :( one embodiment, FIG. 2) of the present embodiment from the embodiment 1 and a pharmaceutical drug delivery system consisting of 2, the drug adsorption in 1, the bottom end surface of the drug delivery system drug release carrier is l round 3. 具体实施方式二:(参见图3、图4)本实施方式药物缓释载体1的底端视图为圆环形4。 DETAILED DESCRIPTION two :( see FIG. 3, FIG. 4) embodiment embodiment of the present drug delivery system is a bottom view of a circular 4. 圆环形的药物缓释载体1的优点在于:既不耽误工作、学习又不耽误治疗。 The annular drug delivery carrier is an advantage in that: neither miss work, study treatment without delay. 以上具体实施方式一和具体实施方式二中药物缓释载体1的材质为多孔缓释材料,如胶原罩、脂质体、聚乙烯醇、醋酸乙烯乙酯、聚-3羟基丁酸酯、 羟基丁酸酯-羟基戊酸酯共聚物(PHBV)、 PHBV与明胶双层结构材料、乙基 DETAILED DESCRIPTION the above specific embodiment and a drug delivery carrier II is a porous material of a sustained release material, such as collagen cover, liposomes, polyvinyl alcohol, ethyl vinyl acetate, poly -3-hydroxybutyrate, hydroxy butyrate - hydroxyvalerate copolymers (PHBV), PHBV-layer structure with the gelatin material, ethyl

纤维素、丙烯酸树脂或神衰果素亲水凝胶其中的任何一种。 Cellulose, acrylic resin, or a hydrophilic gel wherein helicid any one. 缓释药物为任何一种眼药水。 Slow-release drugs for any kind of eye drops. 其制作方法是将所述材料制作的药物缓释载体1浸入药水中3分钟至5小时,然后在无菌的条件下包装即可。 The production method is the sustained release pharmaceutical carrier material 1 is immersed in the solution 3-5 minutes, then unpacked under sterile conditions.

Claims (3)

1、一种结膜囊药物缓释膜,其特征在于结膜囊药物缓释膜由药物缓释载体(1)和药物(2)组成,药物(2)吸附在药物缓释载体(1)内。 1. A pharmaceutical sustained release membrane conjunctiva, conjunctival drug release wherein a drug delivery carrier film (1) and drug (2) the composition, the drug (2) adsorbed on the drug delivery carrier (1).
2、 根据权利要求1所述的结膜囊药物缓释膜,其特征在于药物缓释载体(1)的底端面为圆形(3)。 2. The conjunctival drug release film according to claim 1, characterized in that the drug delivery system (1) is a circular bottom surface (3).
3、 根据权利要求1所述的结膜囊药物缓释膜,其特征在于药物缓释载体(1)的底端视图为圆环形(4)。 3, according to the conjunctival sac drug release film according to claim 1, characterized in that the drug delivery system (1) is a bottom end view of the circular (4).
CNU2007201153508U 2007-01-12 2007-01-12 Conjunctiva sac medicament sustained release film CN201012180Y (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNU2007201153508U CN201012180Y (en) 2007-01-12 2007-01-12 Conjunctiva sac medicament sustained release film

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNU2007201153508U CN201012180Y (en) 2007-01-12 2007-01-12 Conjunctiva sac medicament sustained release film

Publications (1)

Publication Number Publication Date
CN201012180Y true CN201012180Y (en) 2008-01-30

Family

ID=39023966

Family Applications (1)

Application Number Title Priority Date Filing Date
CNU2007201153508U CN201012180Y (en) 2007-01-12 2007-01-12 Conjunctiva sac medicament sustained release film

Country Status (1)

Country Link
CN (1) CN201012180Y (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623400B2 (en) 2011-07-08 2014-01-07 National Chiao Tung University Drug-carrying contact lens and method for fabricating the same
CN104887388A (en) * 2009-06-03 2015-09-09 弗赛特实验室有限责任公司 Anterior segment drug delivery
CN106073986A (en) * 2011-09-14 2016-11-09 弗赛特影像5股份有限公司 Device for treating eyes of patient

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104887388A (en) * 2009-06-03 2015-09-09 弗赛特实验室有限责任公司 Anterior segment drug delivery
CN104887388B (en) * 2009-06-03 2018-01-09 弗赛特影像5股份有限公司 Preceding drug delivery
US10004636B2 (en) 2009-06-03 2018-06-26 Forsight Vision5, Inc. Anterior segment drug delivery
US9937073B2 (en) 2010-06-01 2018-04-10 Forsight Vision5, Inc. Ocular insert apparatus and methods
US8623400B2 (en) 2011-07-08 2014-01-07 National Chiao Tung University Drug-carrying contact lens and method for fabricating the same
CN106073986A (en) * 2011-09-14 2016-11-09 弗赛特影像5股份有限公司 Device for treating eyes of patient

Similar Documents

Publication Publication Date Title
US20020131993A1 (en) Nicotine delivery compositions
ES2571783T3 (en) System contact with the cornea
RU2008134235A (en) The dosage form and method for delivery of addictive drugs
BRPI0511339A (en) horny coverings and wavefront aberration correction to improve vision
BRPI0514733A (en) Silicone hydrogel contact lens
NO326579B1 (en) Ophthalmic pharmaceutical compositions containing brimonidine and timolol and to the use thereof for manufacture of medicament for the treatment of eye
NZ589750A (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
Stern et al. The interaction between Pseudomonas aeruginosa and the corneal epithelium: An electron microscopic study
RU2011136300A (en) Absorbent articles containing multifunctional gel
AR056254A1 (en) MANAGEMENT SYSTEMS INTRAOCULAR OF A SUSTAINED RELEASE DRUG CONTAINING retinoids, a biodegradable polymer AND RELATED METHODS
NZ581767A (en) Formulations of nonopioid and confined opioid analgesics
MX2009000885A (en) Ophthalmic solutions.
NZ600609A (en) Silicone hydrogel contact lenses that gradually release a hydrophobic comfort agent to the wearer
WO2004039351A3 (en) Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
RU2010149612A (en) Aspheric toric intraocular lens
KR101089198B1 (en) Medicinal composition for ophthal use containing acetylated hyaluronic acid
Tangri et al. Basics of ocular drug delivery systems
RU2013153583A (en) Medical products with a uniform density of electric charge and methods for their manufacture
RU2006142861A (en) Use of a viscoelastic composition for a new purpose
JP4308255B2 (en) Ophthalmic transdermal preparation containing a muscarinic receptor agonist
AR080898A1 (en) Photosensitive contact lenses only pupil showing a desirable optical display and comfort
CA2625554A1 (en) Enteric soft capsule comprising valproic acid
CN1124127C (en) Sheet cosmetics
RU2012102772A (en) A pharmaceutical tablet comprising a capsule filled with a liquid
Margo et al. Tarsorrhaphy from accidental instillation of cyanoacrylate adhesive in the eye

Legal Events

Date Code Title Description
C14 Grant of patent or utility model
C17 Cessation of patent right